TY  - JOUR
AB  - Introduction: Epidemiological studies clearly show that thoracic or whole body exposure to ionizing radiation increases the risk of cardiac morbidity and mortality. Radiation-induced cardiovascular disease (CVD) has been intensively studied during the last ten years but the underlying molecular mechanisms are still poorly understood. Areas covered: Heart proteomics is a powerful tool holding promise for the future research. The central focus of this review is to compare proteomics data on radiation-induced CVD with data arising from proteomics of healthy and diseased cardiac tissue in general. In this context we highlight common and unique features of radiation-related and other heart pathologies. Future prospects and challenges of the field are discussed. Expert commentary: Data from comprehensive cardiac proteomics have deepened the knowledge of molecular mechanisms involved in radiation-induced cardiac dysfunction. State-of-the-art proteomics has the potential to identify novel diagnostic and therapeutic markers of this disease.
AU  - Azimzadeh, O.
AU  - Tapio, S.
C1  - 52045
C2  - 43689
CY  - Abingdon
SP  - 987-996
TI  - Proteomics landscape of radiation-induced cardiovascular disease: Somewhere over the paradigm.
JO  - Expert Rev. Proteomics
VL  - 14
IS  - 11
PB  - Taylor & Francis Ltd
PY  - 2017
SN  - 1478-9450
ER  - 

TY  - JOUR
AU  - Tapio, S.
C1  - 50566
C2  - 42531
CY  - Abingdon
SP  - 277-279
TI  - Using proteomics to explore the effects of radiation on the heart - impacts for medicine.
JO  - Expert Rev. Proteomics
VL  - 14
IS  - 4
PB  - Taylor & Francis Ltd
PY  - 2017
SN  - 1478-9450
ER  - 

TY  - JOUR
AB  - Histone post-translational modifications (PTMs), histone variants and enzymes responsible for the incorporation or the removal of the PTMs are being increasingly associated with human disease. Combinations of histone PTMs and the specific incorporation of variants contribute to the establishment of cellular identity and hence are potential markers that could be exploited in disease diagnostics and prognostics and therapy response prediction. Due to the scarcity of suitable antibodies and the pre-requirement of tissue homogenization for more advanced analytical techniques, comprehensive information regarding the spatial distribution of these factors at the tissue level has been lacking. MALDI imaging mass spectrometry provides an ideal platform to measure histone PTMs and variants from tissues while maintaining the information about their spatial distribution. Discussed in this review are the relevance of histones in the context of human disease and the contribution of MALDI imaging mass spectrometry in measuring histones in situ.
AU  - Lahiri, S.*
AU  - Sun, N.
AU  - Buck, A.
AU  - Imhof, A.*
AU  - Walch, A.K.
C1  - 47755
C2  - 37471
CY  - Abingdon
SP  - 275-284
TI  - MALDI imaging mass spectrometry as a novel tool for detecting histone modifications in clinical tissue samples.
JO  - Expert Rev. Proteomics
VL  - 13
IS  - 3
PB  - Taylor & Francis Ltd
PY  - 2016
SN  - 1478-9450
ER  - 

TY  - JOUR
AB  - Imaging mass spectrometry (IMS) is still a relatively young imaging technique that allows molecular mapping of diverse biomolecules in their natural environment. Furthermore, IMS allows for the direct correlation of tissue histology and proteomic, metabolomic or lipidomic information. In recent years, increasing efforts have been made in the development and improvement of IMS, which aid its application in clinical research. In this article, current frontiers of clinical research applications of IMS are discussed in the context of recent developments of IMS technology. Critical stages in planning and realizing clinical studies are highlighted. Finally, a selection of recent prominent examples for successful clinical applications of IMS is presented.
AU  - Neubert, P.
AU  - Walch, A.K.
C1  - 26194
C2  - 32116
SP  - 259-273
TI  - Current frontiers in clinical research application of MALDI imaging mass spectrometry.
JO  - Expert Rev. Proteomics
VL  - 10
IS  - 3
PB  - Expert Reviews
PY  - 2013
SN  - 1478-9450
ER  - 

TY  - JOUR
AB  - MALDI imaging mass spectrometry ('MALDI imaging') is an increasingly recognized technique for biomarker research. After years of method development in the scientific community, the technique is now increasingly applied in clinical research. In this article, we discuss the use of MALDI imaging in clinical proteomics and put it in context with classical proteomics techniques. We also highlight a number of upcoming challenges for personalized medicine, development of targeted therapies and diagnostic molecular pathology where MALDI imaging could help.
AU  - Rauser, S.
AU  - Deininger, S.O.*
AU  - Suckau, D.*
AU  - Höfler, H.
AU  - Walch, A.K.
C1  - 5508
C2  - 27157
SP  - 927-941
TI  - Approaching MALDI molecular imaging for clinical proteomic research: Current state and fields of application.
JO  - Expert Rev. Proteomics
VL  - 7
IS  - 6
PB  - Expert Reviews
PY  - 2010
SN  - 1478-9450
ER  -